Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Executive Vice President & CFO | March 07, 2022 | March 09, 2022 |
| UpHealth, Inc.UPHL · Entity 88003 | Director | January 31, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QUEST DIAGNOSTICS INC
Report date March 07, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,981 |
Ending reported balance
After 2022-03-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-07 · Grant · Acquired 20,780 · Balance 109,456 F1: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). Row 2 · 2022-03-07 · Tax withholding · Disposed 10,475 · Balance 98,981 F2: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d).
F2: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
UpHealth, Inc.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,606 |
Reported balance
After 2024-01-31 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-01-31 · Grant · Acquired 100,000 · Balance 160,606 F2: Subject to the Reporting Person's continued service to the Company, the Restricted Stock Units ("RSUs") shall vest on January 1, 2025; all RSUs shall immediately vest in the event of a Change of Control (as defined in the UpHealth, Inc. 2021 Equity Incentive Plan) of the Company. |
| Common StockSEC Table I · non-derivative | Direct | 60,606 |
Reported balance
Holding disclosure · report date 2024-01-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 60,606 F1: Includes Restricted Stock Units ("Prior RSUs") of UpHealth, Inc. (the "Company"), that are subject to vesting pursuant to previously disclosed vesting schedules. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes Restricted Stock Units ("Prior RSUs") of UpHealth, Inc. (the "Company"), that are subject to vesting pursuant to previously disclosed vesting schedules.
F2: Subject to the Reporting Person's continued service to the Company, the Restricted Stock Units ("RSUs") shall vest on January 1, 2025; all RSUs shall immediately vest in the event of a Change of Control (as defined in the UpHealth, Inc. 2021 Equity Incentive Plan) of the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 1
1 source rowRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.71 · Expires 2028-07-22 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 58,608 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.
F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2018 Filed May 29, 2018 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 61,533 | $58.37 Strike: $58.37 | $3,591,373.55 |
DisclosureSEC source: 0001022079-18-000133 · wf-form4_152762623294219.xml · derivative · entry 4 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,533 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 22, 2018. F4 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on August 19, 2014, the second on August 19, 2015 and the final on August 19, 2016. Read SEC document |
| May 25, 2018 Filed May 29, 2018 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 24,960 | $106.14 | $2,649,229.44 |
DisclosureSEC source: 0001022079-18-000133 · wf-form4_152762623294219.xml · nonDerivative · entry 3 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 22, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $106.00 to $106.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2018 Filed May 29, 2018 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 36,573 | $105.42 | $3,855,452.51 |
DisclosureSEC source: 0001022079-18-000133 · wf-form4_152762623294219.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,160 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 22, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $105.00 to $105.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2018 Filed May 29, 2018 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 61,533 | $58.37 | $3,591,373.55 |
DisclosureSEC source: 0001022079-18-000133 · wf-form4_152762623294219.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 22, 2018. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 00:52 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 6,471 | $101.00 | $653,571.00 |
DisclosureSEC source: 0001022079-18-000094 · wf-form4_152038390649131.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 00:52 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 13,137 | $101.00 | $1,326,837.00 |
DisclosureSEC source: 0001022079-18-000094 · wf-form4_152038390649131.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,671 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 23, 2015, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:03 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 585 | $101.43 | $59,336.55 |
DisclosureSEC source: 0001022079-18-000066 · wf-form4_151994174862559.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,090 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 27, 2018 Filed Mar 7, 2018 00:47 UTC Amendment | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 779 | $101.43 | $79,013.97 |
DisclosureSEC source: 0001022079-18-000093 · wf-form4a_152038364031486.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,534 F1 · date: This Amendment to the original Form 4 filed on March 1, 2018 is made solely to correct an administrative error with respect to the amount of shares reported to the issuer as having been disposed of, as reported on line 4 in Table 1 of the Form 4 as originally filed. F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,092 | $101.43 | $110,761.56 |
DisclosureSEC source: 0001022079-18-000053 · wf-form4_151976754246593.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,675 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2018 Filed Mar 7, 2018 00:45 UTC Amendment | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,454 | $101.43 | $147,479.22 |
DisclosureSEC source: 0001022079-18-000092 · wf-form4a_152038350470927.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,313 F2 · date: This Amendment to the original Form 4 filed on February 27, 2018 is made solely to correct an administrative error with respect to the amount of shares reported to the issuer as having been disposed of, as reported on line 4 in Table 1 of the Form 4 as originally filed. F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 592 | $102.69 | $60,792.48 |
DisclosureSEC source: 0001022079-18-000053 · wf-form4_151976754246593.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,767 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 23, 2018 Filed Mar 7, 2018 00:45 UTC Amendment | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 592 | $102.69 | $60,792.48 |
DisclosureSEC source: 0001022079-18-000092 · wf-form4a_152038350470927.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,767 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 50,764 | $0.00 Strike: $103.57 | $0.00 |
DisclosureSEC source: 0001022079-18-000032 · wf-form4_151925992641098.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,764 Underlying: Common Stock · 50,764 shares Expires 2028-02-19 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-18-000032 · wf-form4_151925992641098.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,359 F1 · shares: Represents an award of restricted share units. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:10 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 7,420 | $98.12 | $728,050.40 |
DisclosureSEC source: 0001022079-17-000097 · wf-form4_148857902274030.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,917 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:10 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 14,309 | $98.12 | $1,403,999.08 |
DisclosureSEC source: 0001022079-17-000097 · wf-form4_148857902274030.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,337 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 13, 2014, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:47 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 625 | $96.42 | $60,262.50 |
DisclosureSEC source: 0001022079-17-000084 · wf-form4_148849120636793.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,028 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 585 | $95.68 | $55,972.80 |
DisclosureSEC source: 0001022079-17-000067 · wf-form4_148831831097670.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,653 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:14 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 57,606 | $0.00 Strike: $95.80 | $0.00 |
DisclosureSEC source: 0001022079-17-000048 · wf-form4_148789167843581.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,606 Underlying: Common Stock · 57,606 shares Expires 2027-02-21 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:14 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 4,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-17-000048 · wf-form4_148789167843581.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,238 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,451 | $93.85 | $136,176.35 |
DisclosureSEC source: 0001022079-17-000022 · wf-form4_148719479171550.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,436 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.